Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2003
09/30/2003CA2112979C Novel derivative of amino-2-naphthyridine, preparation and use thereof
09/30/2003CA2108788C Liposomal prostaglandin formulations
09/30/2003CA2106073C Composition for promoting tissue repair and regeneration
09/30/2003CA2102697C Pyrrolidine derivatives, preparation thereof and drugs containing same
09/30/2003CA2100086C Compositions and methods for alleviating menopausal symptoms
09/30/2003CA2099585C Pharmaceutical compositions
09/30/2003CA2095593C One-pot process
09/30/2003CA2041579C Dosage form
09/29/2003CA2423915A1 Process for producing nanoparticles of paclitaxel and albumin
09/29/2003CA2423884A1 Improved paclitaxel-based antitumor formulation
09/29/2003CA2423248A1 Polymorphic forms of fasidotril, procedures for their preparation and pharmaceutical compounds that contain them
09/28/2003CA2379370A1 Carboxylic acid derivatives of 3-hydroxy-4-oxo-1,4-dihydropyridine as iron chelators
09/25/2003WO2003079403A2 Oligo(ethylene glycol)-terminated 1,2-dithiolanes and their conjugates useful for preparing self-assembled monolayers
09/25/2003WO2003079020A2 Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
09/25/2003WO2003078959A2 Methods for shp1 mediated neuroprotection
09/25/2003WO2003078658A2 Methods for diagnosing and treating schizophrenia
09/25/2003WO2003078623A1 Functional molecule and process for producing the same
09/25/2003WO2003078595A2 Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response
09/25/2003WO2003078579A2 Compositions and methods for treating emphysema
09/25/2003WO2003078578A2 Modulation of the immune response through the manipulation of arginine levels
09/25/2003WO2003078574A2 Novel metabolic targets and markers
09/25/2003WO2003078467A1 Enhancement of iron chelation therapy
09/25/2003WO2003078441A1 Aminomethyl-substituted thiazolobenzimidazole derivative
09/25/2003WO2003078440A1 Broad-spectrum cephem compounds
09/25/2003WO2003078438A1 Carbamates as hiv protease inhibitors
09/25/2003WO2003078437A1 Methods and compositions comprising nitric oxide donors and opioid analgesics
09/25/2003WO2003078435A1 Pyrazolo(1,5-a)pyridine derivatives as neurotransmitter modulators
09/25/2003WO2003078434A1 Ethane-1,2-diamino-bis[(2r)-2-bromo-3-phenylpropanoate], method for production and use thereof
09/25/2003WO2003078433A1 Process for preparing crystalline form i of cabergoline
09/25/2003WO2003078431A1 Aza-bicyclic n-biarylamides with affinity for the alpha-7 nicotinic acetylcholine receptor
09/25/2003WO2003078430A1 Amides of acetic and propionic acids
09/25/2003WO2003078429A1 Micronized crystalline tiotropium bromide
09/25/2003WO2003078428A1 Difurylglycolic acid tropenol esters used as anticholinesterase drugs
09/25/2003WO2003078425A1 Novel crystalline form of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy]benzyl]thiazolidine-2,4-dione potassium salt
09/25/2003WO2003078422A1 Novel pyridone derivative
09/25/2003WO2003078421A1 Piperidine derivatives useful as modulators of chemokine receptor activity
09/25/2003WO2003078416A1 Therapeutic ion channel blocking agents and methods of use thereof
09/25/2003WO2003078413A1 Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity
09/25/2003WO2003078411A1 C3-cyano epothilone derivatives
09/25/2003WO2003078410A1 Cyclic etheramine derivatives and their use for the treatment of tumors
09/25/2003WO2003078408A1 Crystalline parecoxib sodium
09/25/2003WO2003078404A1 Pyrimidine derivatives
09/25/2003WO2003078403A2 Derives d’aminoindazoles comme inhibiteurs de proteine-kinase
09/25/2003WO2003078402A1 Indazoles substituted with an anti-cancerous activity
09/25/2003WO2003078401A1 Preventive and/or therapeutic agent for hypoxic ischemic brain disorder
09/25/2003WO2003078400A1 Neurotensin active 2,3-diaryl-pyrazolidine derivatives
09/25/2003WO2003078398A1 NON-PEPTIDE GnRH ANTAGONISTS
09/25/2003WO2003078397A1 Hetero-bridge substituted 8-arylquinoline pde4 inhibitors
09/25/2003WO2003078395A1 Piperidine derivatives useful as modulators of chemokine receptor activity
09/25/2003WO2003078387A1 Formulations of anthraquinone derivatives
09/25/2003WO2003078386A1 Naphthylsemicarbazone, naphthylhydrazone, naphthylthiosemicarbazone, and naphthylthiohydrazone compounds and therapeutic use thereof
09/25/2003WO2003078379A1 AMORPHOUS Hmg-CoA REDUCTASE INHIBITORS OF DESIRED PARTICLE SIZE
09/25/2003WO2003078376A1 Nk1 antagonists
09/25/2003WO2003078367A2 Benzyl alcohol derivatives and their use as antimicrobial agents
09/25/2003WO2003077999A1 Combination ofa cdk inhibitor and 5-fu for the treatment of cancer
09/25/2003WO2003077998A1 Use of asc-1 inhibitors to treat neurological and psychiatric disorders
09/25/2003WO2003077951A1 Percutaneous absorption promoters and compositions for treating athlete’s foot
09/25/2003WO2003077949A2 Methods of treating diabetes using pde 11a inhibitors
09/25/2003WO2003077935A1 Use of enzyme inhibitors with aminopeptidase n and/or dipeptidylpeptidase iv activities and pharmaceutical preparations produced therefrom for the therapy and prevention of dermatological diseases with seborrhoeic hyperproliferation and altered differentiation states
09/25/2003WO2003077934A1 Use of a biotechnological honey substitute in a cosmetic or dermatological composition
09/25/2003WO2003077932A1 Remedies for lung cancer
09/25/2003WO2003077930A1 Use of at least one quercetine flavonoid for increasing the level of useful short-chain fatty acids in the lower intestinal tract
09/25/2003WO2003077929A1 Fosinopril formulation
09/25/2003WO2003077928A1 Peptide analogues and uses thereof
09/25/2003WO2003077927A1 Sulfatase inhibiting progestogen-only contraceptive regimens
09/25/2003WO2003077926A1 Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens
09/25/2003WO2003077925A1 Sulfatase inhibiting continuous progestogen contraceptive regimens
09/25/2003WO2003077924A1 Continuous sulfatase inhibiting progestogen hormone replacement therapy
09/25/2003WO2003077923A1 Progesterone oral drug delivery system
09/25/2003WO2003077920A1 Pharmaceutical compositions comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo’1,5-bipyridazine in nanoparticulate form
09/25/2003WO2003077919A1 Fluorinated 4-azasteroid derivatives as androgen receptor modulators
09/25/2003WO2003077918A1 Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
09/25/2003WO2003077917A1 Axon regeneration with pkc inhibitiors
09/25/2003WO2003077916A1 Use of proton pump inhibitors for the treatment of noncardiac chest pain
09/25/2003WO2003077915A1 Use of rapamycin for inhibiting of cell death
09/25/2003WO2003077914A1 N3 alkylated benzimidazole derivatives as mek inhibitors
09/25/2003WO2003077913A1 Peptide deformylase inhibitors
09/25/2003WO2003077912A1 Method of treatment and/or prophylaxis
09/25/2003WO2003077911A1 Photodynamic therapy for pre-melanomas
09/25/2003WO2003077910A1 Methods of treatment with selective ep4 receptor agonists
09/25/2003WO2003077909A1 Medical use of captopril for the treatment and prophylaxis of cancer
09/25/2003WO2003077908A1 Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
09/25/2003WO2003077907A1 Azetidine derivatives as ccr-3 receptor antagonists
09/25/2003WO2003077906A1 Cyclic etheramine derivatives as medicaments for malignant tumors
09/25/2003WO2003077905A1 Use of an l-ascorbic acid salt to prepare a pharmaceutical composition for ophtalmic topical use capable of improving the level of l-ascorbic acid in the eye
09/25/2003WO2003077904A1 Biological activity-promoting compositions containing soybean germ-origin isoflavone aglycon
09/25/2003WO2003077901A1 Preventing and/or treating cardiovascular disease and/or associated heart failure
09/25/2003WO2003077900A1 A unifying mechanism and methods to prevent cancer and neurodegenerative diseases
09/25/2003WO2003077899A1 Anticancer composition
09/25/2003WO2003077898A1 Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
09/25/2003WO2003077897A1 Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
09/25/2003WO2003077896A1 Drug combination therapy
09/25/2003WO2003077895A1 Compositions for diabetes
09/25/2003WO2003077893A2 Compositions for treating digestive functional pathologies
09/25/2003WO2003077892A2 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide for treating ang ii-mediated diseases
09/25/2003WO2003077890A1 Hormone-containing transdermal therapeutic system with an active substance reservoir based on vinylacetate-vinylpyrrolidone copolymer with improved cohesion.
09/25/2003WO2003077888A2 Compressed tablets comprising microcapsules with modified release
09/25/2003WO2003077886A1 Method of manufacturing chemical-containing composite particles
09/25/2003WO2003077885A2 Free-base formulations of local anesthetics
09/25/2003WO2003077882A2 Preparation of sterile stabilized nanodispersions
1 ... 5328 5329 5330 5331 5332 5333 5334 5335 5336 5337 5338 5339 5340 5341 5342 5343 5344 5345 5346 5347 5348 ... 7860